# Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia

> **NCT02072785** · PHASE3 · UNKNOWN · sponsor: **Nanjing Luye Sike Pharmaceutical Co., Ltd.** · enrollment: 480 (estimated)

## Conditions studied

- Adult Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Vincristine Sulfate Liposome
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT02072785
- **Lead sponsor:** Nanjing Luye Sike Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2014-03-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02072785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02072785, "Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02072785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*